Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
7
×
boston blog main
boulder/denver blog main
boulder/denver top stories
clinical trials
7
×
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
novartis
7
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
7
×
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston top stories
fda
abbvie
biogen
cancer immunotherapy
gene therapy
glaxosmithkline
immunotherapy
zolgensma
amgen
bristol-myers squibb
cancer
What
roundup
7
×
bio
news
biotech
days
drug
ipo
nash
new
abbvie’s
according
acquisitions
advantages
ahead
akcea
america
announced
approval
august
bar
biofourmis
biogen
biogen’s
biopharmaceutical
brings
bucks
busy
cancer
cases
celebrate
centers
ceo
chance
cigarettes
collabs
companies
continues
control
convo
convoluted
Language
unset
Current search:
biotech
×
novartis
×
roundup
×
" san francisco top stories "
×
" clinical trials "
×
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More